Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | VCAM1 | P19320 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2107736 | 0.88 | L3MBTL1 (0.37) | L3MBTL1POLBNPC1MAPTRAB9A | |
| SCHEMBL1688819 | 0.85 | L3MBTL1 (0.48) | L3MBTL1VCAM1POLBNPC1MAPT | |
| SCHEMBL2107084 | 0.82 | SMN1; SMN2 (0.52) | POLBNPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL4703700 | 0.82 | KDM4E (0.43) | L3MBTL1POLBALDH1A1TLR8KDM4E | |
| SCHEMBL27771633 | 0.81 | L3MBTL1 (0.42) | L3MBTL1VCAM1POLBNPC1MAPT | |
| SCHEMBL3247563 | 0.76 | CDKN1A (0.53) | ALDH1A1TLR8KDM4EBRAF | |
| SCHEMBL1688817 | 0.75 | KDM4E (0.41) | L3MBTL1POLBNPC1MAPTRAB9A | |
| SCHEMBL4703709 | 0.74 | KDM4E (0.46) | L3MBTL1POLBALDH1A1TLR8KDM4E | |
| SCHEMBL2107212 | 0.73 | NTRK1 (0.60) | L3MBTL1POLBNPC1MAPTALDH1A1 | |
| SCHEMBL4701446 | 0.73 | KDM4E (0.42) | L3MBTL1POLBALDH1A1TLR8KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158632-B2 | Pyrazolo[1,5-a]pyrimidines, processes, uses and compositions | FERRER INTERNACIONAL, S.A. (ES) | 2012-04-17 | — | — | US | claimed |
| EP-2059521-B1 | PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES AND COMPOSITIONS | FERRER INT (ES) | 2010-06-02 | — | — | EP | claimed |
| US-20090264448-A1 | PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES AND COMPOSITIONS | FERRER INTERNATIONAL, S.A. (ES) | 2009-10-22 | — | — | US | claimed |
| EP-1884516-A1 | Pyrazolo[1,5-a]pyrimidines, processes, uses and compositions | FERRER INTERNACIONAL, S.A. (ES) | 2008-02-06 | — | — | EP | claimed |
| US-8158632-B2 | Pyrazolo[1,5-a]pyrimidines, processes, uses and compositions | FERRER INTERNACIONAL, S.A. (ES) | 2012-04-17 | — | — | US | disclosed |
| EP-2059521-B1 | PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES AND COMPOSITIONS | FERRER INT (ES) | 2010-06-02 | — | — | EP | disclosed |
| US-20090264448-A1 | PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES AND COMPOSITIONS | FERRER INTERNATIONAL, S.A. (ES) | 2009-10-22 | — | — | US | disclosed |
| EP-2059521-A1 | PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES AND COMPOSITIONS | Ferrer Internacional, S.A. (ES) | 2009-05-20 | — | — | EP | disclosed |
| WO-2008015253-A1 | PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES AND COMPOSITIONS | FERRER INTERNACIONAL, S.A. (ES) | 2008-02-07 | — | — | WO | disclosed |
| EP-1884516-A1 | Pyrazolo[1,5-a]pyrimidines, processes, uses and compositions | FERRER INTERNACIONAL, S.A. (ES) | 2008-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264448-A1 | PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES AND COMPOSITIONS | P2RX5, GABRA5, P2RX1 | L3MBTL1 3610/4885VCAM1 4317/4885POLB 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.